openPR Logo
Press release

Biopharma PEG Provides Monodisperse PEGs In Drug Development

Biopharma PEG Provides Monodisperse PEGs In Drug Development

Monodisperse PEG products usually are organic compounds with a molecular weight of less than 1000. Monodispersed PEG linkers are pure compounds with a single molecular weight. Monodisperse polyethylene glycol(PEG) molecular weight is fixed. It can not be obtained by polymerization. It must be by the appropriate reaction of the basic polyethylene glycol fragment.

With advancements in both synthetic and purification chemistry over the past two decades, monodispersed PEG linkers have become more commercially viable.  Monodispersed PEG linkers have been found to be beneficial in drug design, specifically in small molecule drugs. Some of the problems that are often seen in small molecule drugs include its ability to be easily removed from the body, low solubility and less target-specificity. 

The introduction of monodispersed PEG linkers to small molecule drugs increases the drug's solubility and molecular weight. This may allow an extended drug half-life in the body. The use of monodispersed PEG linkers has also improved drug development with its ability to produce homogeneous PEGylated drugs with a specific molecular weight.

The team of Biopharma PEG Scientific Inc. owns the most qualified and talented synthetic and medicinal chemists. We can provide a wide range of high purity monodispersed PEG products of multi functionalized groups in milligram to hundreds of kilograms or greater with GMP standard manufacturing capability. With our strong expertise in modern chemistry, innovative & novel PEG technology and state-of-the-art equipment, Biopharma PEG Scientific Inc. can help our customers to accelerate their research through cost-effective and efficient solutions. 

Biopharma PEG Scientific Inc., founded in 2013, is a biotechnology-oriented company in Watertown, Massachusetts. We are dedicated to providing high purity monodisperse PEG raw materials and monodisperse PEG derivatives with an extensive variety of functional groups, from grams to kilograms batch size in both non-GMP and GMP grade.

Biopharma PEG Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA
TEL: 1-857-366-6766
Fax: 617-206-9595
Email: sales@biochempeg.com
Website:https://www.biochempeg.com/

As a leading manufacturer of PEG derivatives, Biopharma PEG is fully competent and dedicated to serving mRNA vaccine companies with high purity PEG lipids. With comprehensive and advanced platforms, the company provides PEG derivatives and related products to customers worldwide to meet new drug delivery goals.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biopharma PEG Provides Monodisperse PEGs In Drug Development here

News-ID: 2662741 • Views:

More Releases from Biopharma PEG Scientific Inc.

Biopharma PEG Supplies Cholesterol (Plant-Derived) Used As Excipients for Lipid Nanoparticles (LNPs)
Biopharma PEG Supplies Cholesterol (Plant-Derived) Used As Excipients for Lipid …
Cholesterol, a derivative of cyclopentane polyhydrophenanthrene, is the main steroid compound in mammals. Most of the traditional cholesterol comes from animal brainstem and lanolin, which is of animal origin and has the risk of carrying animal viruses. Biopharma PEG innovatively uses plant sterols as starting materials to prepare plant-derived cholesterol (CAS NO.: 57-88-5) through biological fermentation and green synthesis, eliminating the generation and carrying of viruses from the source. Cholesterol has
Development Trends And Potential Challenges of PROTACs
Development Trends And Potential Challenges of PROTACs
PROTAC technology has been in development for more than 20 years. PROTAC proof-of-concept studies date back to 2001, when Crews' team tested the possibility of artificially induced intracellular protein degradation with a peptide that was too large in molecular weight and required cells to penetrate the peptide to improve cell permeability. The discovery of the first small molecule PROTAC and the subsequent small molecule E3 ligand, reported in 2008, greatly
ADC Drugs For Breast Cancer Treatment
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment. On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by
History Development of Hydrogels
History Development of Hydrogels
Hydrogels are composed of hydrophilic polymers, whose three-dimensional network structure can not only absorb a large amount of water, but also be used to carry drugs. Hydrogels prepared with suitable materials have the characteristics of high biocompatibility, mechanical and viscoelastic control. Since the term was coined in the late 19th century, hydrogels have been widely used in drug delivery, wound dressing, tissue engineering, and hygiene products. This article mainly introduces

All 5 Releases


More Releases for Monodisperse

The Advantages of Monodisperse PEG From In Drug Development
Monodisperse PEG products usually are organic compounds with a molecular weight of less than 1000. Monodispersed PEG linkers are pure compounds with a single molecular weight. In contrast, polydisperse PEGs linkers contain variations in molecular weight with an average molecular weight. The use of polydisperse PEGs linkers in drug development has led to problems in biological applications due to steric hindrance and binding. With advancements in both synthetic and purification chemistry over the
The Advantages of Monodisperse PEG In Drug Development?
Monodisperse PEG products usually are organic compounds with a molecular weight of less than 1000. Monodispersed PEG linkers are pure compounds with a single molecular weight. In contrast, polydisperse PEGs linkers contain variations in molecular weight with an average molecular weight. The use of polydisperse PEGs linkers in drug development has led to problems in biological applications due to steric hindrance and binding. With advancements in both synthetic and purification chemistry over the
Immunotherapy, The Most Prominent Topic In Skin Cancer Research
A report published on May, 21, 2019 highlights the different research areas in the field of skin cancer, showing that immunotherapy is the most prominent topic and reveals the countries that are driving this research. The study, “Melanoma Research Insights: Impact, Trends, Opportunities”, released during Skin Cancer Awareness Month by information analytics business Elsevier, maps and analyses academic research on melanoma globally between 2013-2018. Findings in the report highlight that melanoma
Two New Diabetes Drugs Benefit For The Heart And Kidneys
Two new medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society. One class of drugs, known as SGLT2 inhibitors, has a clear benefit over the
Biochempeg developed a series of PEG compounds used for Semaglutide
Type 2 diabetes is the most common form of diabetes. Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin. Biochempeg has developed and can supply some key intermediates of Semaglutide. Semaglutide(trade names: Rybelsus,Ozempic) is a medication for the treatment of type 2 diabetes. It was discovered in 2012, by a team of researchers
LANXESS Makes Innovative Contribution to Industrial Water Treatment
LANXESS’ new generation of gel-type cation exchange resins deliver improved chemical and physical stability, prolong service life Singapore, 21 December 2009 – Specialty chemicals group LANXESS has developed a new generation of high-performance gel-type cation exchange resins for industrial water treatment. Lewatit MonoPlus S 108 and Lewatit MonoPlus S 108 H are the result of several years of research work, and are noted above all for an excellent leaching behavior and